-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2159 Deferiprone Has a Dose-Dependent Effect on Liver Iron ConcentrationClinically Relevant Abstract

Thalassemia and Globin Gene Regulation
Program: Oral and Poster Abstracts
Session: 112. Thalassemia and Globin Gene Regulation: Poster II
Sunday, December 6, 2015, 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Alessia Pepe1*, Tommaso Casini2*, Liana Cuccia3*, Francesco Sorrentino4*, Rosamaria Rosso5*, Paolo Ricchi6*, Aurelio Maggio7, Maria Giovanna Neri1*, Maria Chiara Resta8*, Valentina Vinci9*, Vincenzo Positano1* and Antonella Meloni1*

1CMR Unit, Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Italy
2Centro Talassemie ed Emoglobinopatie, Ospedale Meyer, Firenze, Italy
3Unità Operativa Complessa Ematologia con Talassemia, ARNAS Civico, Palermo, Italy
4U.O.S. Dipartimentale - DH Talassemici, Ospedale, Roma, Italy
5U.O. Talassemie ed Emoglobinopatie, Ospedale "Ferrarotto" - Azienda Ospedaliero-Universitaria Policlinico "Vittorio Emanuele", Catania, Italy
6Unità Operativa Semplice Dipartimentale Malattie Rare del Globulo Rosso, Azienda Ospedaliera di Rilievo Nazionale, Napoli, Italy
7Ematologia II con Talassemia, Ospedale, Palermo, Italy
8Struttura Complessa di Radiologia, Ospedale "SS. Annunziata" ASL Taranto, Taranto, Italy
9Istituto di Radiologia, Az. Osp. "Garibaldi" - Presidio Ospedaliero Nesima, Catania, Italy

Purpose: The aim of this multi-centre study was to retrospectively assess in thalassemia major (TM) if deferiprone (DFP) had a dose-dependent effect on liver iron concentration (LIC) assessed by quantitative magnetic resonance imaging (MRI).

Methods: Among the 958 TM patients enrolled in the MIOT (Myocardial Iron Overload in Thalassemia) network, we identified hose with an MRI follow up study at 18±3 months who had been received DFP monotherapy and had no changes in dose of DFP between the 2 MRI scans. Patients were divided into two groups according to the DFP dose: 79 patients with ≤ 75 mg/kg/d (group 1) and 39 with > 75 mg/kg/d (group 2).

Hepatic iron overload was measured by the T2* multiecho technique and T2* values were converted into LIC values using the calibration curve introduced by Wood et al.

Results: The two groups had comparable baseline MRI LIC values. The table shows the evolution of different iron overload risk classes between the baseline and the FU MRI. The percentage of patients that worsened their status was significantly higher in group 1 than in group 2 (26.6% vs 7.7%; P=0.016).

Subgroup analysis in patients with hepatic iron overload at baseline (MRI LIC > 3mg/g/dw) was conducted: 48 patients from group 1 (DFP dose: mean 70.6±11.2 mg/kg/d, median 75 mg/kg/d) and 30 from group 2 (DFP dose: mean 85.2±6.6 mg/kg/d, median 84 mg/kg/d). The two subgroups had comparable baseline MRI LIC values (10.2±8.1 mg/g dw vs 11.1±8.7 mg/g dw (P=0.314). While the mean change in subgroup 2 ( -1.8±6.3mg/g/dw, P=0.131) was more favourable than in subgroup 1 (+0.1±7.7 mg/g/dw, P=0.903), the change in MRI LIC values did not reach statistical significance between the two subgroups (P=0.579) (Figure 1), which may be due to small cohort evaluated.

Conclusions: In TM patients the worsening in MRI LIC can be prevented by increasing the dose of deferiprone above the widely used regimen of 75 mg/kg body weight. Our results are consistent with the iron balance studies performed by Grady RW et al.

 

 

Table 1. Evolution of different iron overload risk classes between the baseline and the FU MRI. The underlined numbers represent the patients who remained in the same risk class.

 

DFP dose ≤ 75 mg/kg/d (N=79)

FU LIC

<3 mg/g dw

3-7 mg/g dw

7-15 mg/g dw

≥15 mg/g dw

Baseline LIC

 <3 mg/g dw (N=31)

21

7

3

0

 3-7 mg/g dw (N=22)

10

4

6

2

 7-15 mg/g dw (N=14)

0

6

5

3

 ≥15 mg/g dw (N=12)

1

0

5

6

 Total at the FU

32

17

19

11

DFP dose > 75 mg/kg/d (N=39)

FU LIC

<3 mg/g dw

3-7 mg/g dw

7-15 mg/g dw

≥15 mg/g dw

Baseline LIC

 <3 mg/g dw (N=9)

6

2

1

0

 3-7 mg/g dw (N=14)

3

11

0

0

 7-15 mg/g dw (N=8)

0

4

4

0

 ≥15 mg/g dw (N=8)

1

0

2

5

 Total at the FU

10

17

7

5

 

 

 

Figure 1. Changes of MRI LIC values in patients with basal MRI LIC > 3 mg/g/dw.

 

 

Disclosures: Pepe: Chiesi: Speakers Bureau ; ApoPharma Inc: Speakers Bureau ; Novartis: Speakers Bureau .

*signifies non-member of ASH